Browsing Tag
NASDAQ: SEPN
1 post
What this Phase 1 milestone reveals about the next wave of GPCR-driven endocrine therapeutics
What does Septerna’s Phase 1 milestone mean for GPCR-driven endocrine innovation? Read how SEP-479 could reshape biotech strategy and market sentiment.